Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial

Vincent Meininger, Pierre François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, James B. Caress, Merit Cudkowicz, Stephen J. Kolb, Dale Lange, P. Nigel Leigh, Thomas Meyer, Stefano Milleri, Karen E. Morrison, Richard W. Orrell, Gary Peters, Jeffrey D. Rothstein, Jeremy Shefner, Arseniy Lavrov, Nicola Williams, Phil OverendJeffrey Price, Stewart Bates, Jonathan Bullman, David Krull, Alienor Berges, Bams Abila, Guy Meno-Tetang, Jens Wurthner

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences